Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
United States Naval Medical Center, San Diego
ClinicalTrials.gov Identifier:
NCT01668069
First received: August 15, 2012
Last updated: July 11, 2013
Last verified: July 2013
  Purpose

Our purpose is to determine whether ondansetron, a commonly used antiemetic, is equivalent in efficacy to the combination of pyridoxine and doxylamine, the currently recommended first line therapy for nausea and vomiting in pregnancy by the American Congress of Obstetricians and Gynecologists (ACOG). Since both treatments are safe in pregnancy, many physicians are using ondansetron as first line in practice. Despite this practice and the recommendations from ACOG, there is not data to suggest that ether practice is superior. This will be the first prospective, randomized, double blind, controlled trial comparing the two treatments. We hypothesize that ondansetron will be equally efficacious in reducing nausea and episodes of emesis. By alleviating nausea and vomiting associated with pregnancy, patients will likely benefit from less Emergency Department visits, urgent clinic visits, and admissions for progression to hyperemesis gravidarum.


Condition Intervention
Vomiting of Pregnancy
Drug: Ondansetron
Drug: Doxylamine and pyridoxine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy

Resource links provided by NLM:


Further study details as provided by United States Naval Medical Center, San Diego:

Primary Outcome Measures:
  • Reduction of nausea on the VAS (Visual Analog Scale) [ Time Frame: 5 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reduction in vomiting on the VAS [ Time Frame: 5 days ] [ Designated as safety issue: No ]
  • Any adverse effects caused by the study medications. [ Time Frame: 5 days ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: October 2012
Study Completion Date: April 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ondansetron Drug: Ondansetron
Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
Other Name: Zofran
Experimental: Doxylamine and Pyridoxine (vitamin B6) Drug: Doxylamine and pyridoxine
Pyridoxine 25mg and doxylamine 12.5mg to be taken orally every 8 hours for 5 days.
Other Name: Vitamin B6

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women who are less than 16 weeks pregnant by last menstrual period or ultrasound
  • Greater than 18 years of age
  • English speaking
  • No significant visual or hearing impairment
  • Requesting treatment for nausea associated with pregnancy

Exclusion Criteria:

  • If nausea or vomiting preexisted the pregnancy
  • Requires hospitalization at the time of initial enrollment
  • Already taking anti-emetics to include metoclopramide, ondansetron, doxylamine, pyridoxine, or promethazine
  • The patient has an allergy to either study regimen
  • If they are unable to return for a follow up visit in 1 week
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668069

Locations
United States, California
Naval Medical Center, San Diego
San Diego, California, United States, 92134
Sponsors and Collaborators
United States Naval Medical Center, San Diego
Investigators
Principal Investigator: Lauren G Oliveira, DO United States Naval Medical Center, San Diego
  More Information

No publications provided

Responsible Party: United States Naval Medical Center, San Diego
ClinicalTrials.gov Identifier: NCT01668069     History of Changes
Other Study ID Numbers: NMCSD-2011-0151
Study First Received: August 15, 2012
Last Updated: July 11, 2013
Health Authority: United States: Federal Government

Keywords provided by United States Naval Medical Center, San Diego:
nausea
vomiting
pregnancy
ondansetron
doxylamine
vitamin B6
pyridoxine

Additional relevant MeSH terms:
Pregnancy Complications
Vomiting
Signs and Symptoms
Signs and Symptoms, Digestive
Doxylamine
Doxylamine succinate
Ondansetron
Pyridoxal
Pyridoxine
Vitamin B 6
Vitamin B Complex
Vitamins
Anti-Anxiety Agents
Antiemetics
Antipruritics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dermatologic Agents
Gastrointestinal Agents
Growth Substances
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Micronutrients
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 30, 2014